Nov 9, 2023
It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for...
Sep 20, 2023
Charles Joynson, WaveData MD, puts a spotlight on Lustral Tabs as we explore the product lifecycle post LOE. Before generics were launched in November 2005 there was a high degree of similarity between the price of the UK and PI (parallel import) packs of Lustral Tabs...
Aug 24, 2023
Normally we expect branded devices to maintain their pharmacy purchase prices over long periods of time. However, here this is not the case. Charles Joynson, WaveData MD investigates further. Looking at the long term market price trends of Freestyle Optium Test Strips...
May 9, 2023
There are two primary ways in which shortages are flagged for pharmacists and dispensers. The first is the granting of a concession for generic products and the second is the product’s addition to the NHS’ serious shortage protocols (SSP) list. These have both been...
Feb 7, 2023
VPAS continues to be one of the top priorities for the UK Pharma Industry. A week or so ago, we undertook some analysis on Originator Brands, assessing profitability and UK market attractiveness. If the rebate is unsustainable, and results in loss making products for...
Jan 30, 2023
Although the aim of the VPAS scheme is to support innovation and better patient outcomes, alongside keeping a lid on the NHS drug budget, could the scheme actually be doing the opposite? If the rebate is unsustainable, and results in loss making products for...
